Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer.

ABSTRACT:

Purpose

An estimated 25% of patients with biliary tract cancer (BTC) do not undergo genotyping, representing a missed opportunity for therapeutic targeting.

Methods

Cell-free DNA (cfDNA) and matched tumor sample from patients with BTC were analyzed using targeted next-generation sequencing (NGS) assay and compared. We sought to define the molecular profile of cancer-derived cfDNA, frequency of OncoKB level 1/2 alterations, plasma:tumor genotype concordance, the prognostic impact of cfDNA, and clonal evolution after targeted therapy progression.

Results

cfDNA-based genotyping was performed on 297 blood samples from 170 patients with BTC. The most frequently altered genes were TP53 (29%), FGFR2 (16%), ARID1A (13%), CDKN2A (11%), and KRAS</

SUBMITTER: Cowzer D 

PROVIDER: S-EPMC12443323 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature